Page 1,740«..1020..1,7391,7401,7411,742..1,7501,760..»

Texas May Be First To Allow Stem Cell Therapies For Desperate Patients – Vocativ

Posted: Published on May 31st, 2017

A bill may soon grant Texans greater access to unapproved but promising stem cell therapies, Stat News reports. Its passage would make Texasthe first state to back the technology, which has not been approved by federal regulators and many experts consider risky. The bill, HB 810, is intended to give people with chronic diseases or terminal illnesses access to investigational stem cell treatments those that are being evaluated in clinical trials or that has in general not been approved by the FDA. With a doctors approval, patients who have had not had success withconventional treatments would be allowedto seek stem cell therapiesat any clinic that offers it, as long as the treatment is givenby a licensed physician and approved by an institutional review board. Already, hundreds of largely unregulated clinics around the country are quietly operatingunder regulatory loopholes; few states have taken legal steps to advance or hinder patient access to them. Texas has welcomed these clinics for years. In 2011, then-governor Rick Perry received an injection of stem cells intended to help heal his spine after spinal fusion surgery. Lets get Texas in on the ground floor and invest in adult stem cell research, the one area of that … Continue reading →

Posted in Stem Cell Research | Comments Off on Texas May Be First To Allow Stem Cell Therapies For Desperate Patients – Vocativ

New tools strengthen old link between autism, mitochondria – Spectrum

Posted: Published on May 30th, 2017

Zoran Brkanac Associate professor, University of Washington Associate professor, University of Washington Most research into the genetic basis of autism focuses on the DNA nestled inside a cells nucleus. Scientists unravel the DNA and study the genes that code for proteins, with the goal of identifying the molecular pathways involved. They then aim to develop treatments that target these pathways. So far, studies have implicated hundreds of nuclear genes in autism, with about 100 genes emerging as strong candidates1,2. But the nucleus may not be the only source of genes involved in autism. DNA also exists inside cellular compartments, or organelles, called mitochondria. These organelles are the powerhouses of cells. They generate a molecule called adenosine triphosphate (ATP), which serves as the main source of cellular energy. Each mitochondrion contains thousands of copies of a circular genome that codes for 13 of the 96 proteins needed to build the mitochondrias core ATP machinery. Unlike nuclear DNA, mitochondrial DNA (mtDNA) is inherited only from the mother. This year, my colleagues and I published results suggesting that variants of mitochondrial genes contribute to autism in some cases, by teaming up with genes in the nucleus. Over the past decade, several lines of … Continue reading →

Posted in BioInformatics | Comments Off on New tools strengthen old link between autism, mitochondria – Spectrum

'Young Sheldon', 'Grey's Anatomy' Spinoff Among 13 U.S. Series Picked Up By CTV LA Screenings – Deadline

Posted: Published on May 30th, 2017

Deadline 'Young Sheldon', 'Grey's Anatomy' Spinoff Among 13 U.S. Series Picked Up By CTV LA Screenings Deadline They are comedies The Big Bang Theory spinoff Young Sheldon, Me, Myself & I from CBS and Roseanne revival and The Mayor from ABC. Dramas include Shondaland's untitled Grey's Anatomy spinoff, which will premiere midseason, and new legal drama ... CTV Picks Up 'Young Sheldon,' Marvel's 'Inhumans' and 'The Gifted'Hollywood Reporter A Stroke of Genius: YOUNG SHELDON Leads CTV Acquisitions for 2017/18 SeasonCanada NewsWire (press release) all 3 news articles » See the original post: 'Young Sheldon', 'Grey's Anatomy' Spinoff Among 13 U.S. Series Picked Up By CTV LA Screenings - Deadline … Continue reading →

Posted in Anatomy | Comments Off on 'Young Sheldon', 'Grey's Anatomy' Spinoff Among 13 U.S. Series Picked Up By CTV LA Screenings – Deadline

AMO Pharma Announces FDA Fast Track Designation For AMO-02 For Treatment Of Congenital Myotonic Dystrophy – PR Newswire (press release)

Posted: Published on May 30th, 2017

"Congenital myotonic dystrophy is a devastating neuromuscular disease where affected patients currently have no treatment options available," said Michael Snape, chief executive officer of AMO Pharma. "The designation of Fast Track status for our development program for AMO-02 highlights both the urgent need for a treatment for patients and the potential for this novel therapy to offer a major advance in their care in the years ahead." AMO-02 (tideglusib) is in clinical stage development for the treatment of the severe form of myotonic dystrophy known as congenital DM1. In cellular and animal models of congenital DM1 and Duchenne muscular dystrophy, as well as in muscle biopsies from patients, activity of glycogen synthase kinase 3 beta (GSK3) has been shown to be increased. Inhibitors of GSK3 have been shown to correct the activity of RNA binding proteins, such as CUGBP1, in animal models of DM1. AMO-02 is an inhibitor of GSK3 that has demonstrated pre-clinical efficacy in transgenic models and reversal of muscle cell differentiation deficits in ex vivo tissue samples derived from patients with congenital DM1. "Our ongoing phase 2 clinical trial for AMO-02 in the UK is the first sponsor-led clinical study in the treatment of congenital myotonic dystrophy … Continue reading →

Posted in Muscular Dystrophy Treatment | Comments Off on AMO Pharma Announces FDA Fast Track Designation For AMO-02 For Treatment Of Congenital Myotonic Dystrophy – PR Newswire (press release)

Local boy, police accompany teen with cerebral palsy to formal – FOX 29 News Philadelphia

Posted: Published on May 30th, 2017

WILDWOOD, NJ (WTXF) - A local boy who asked a girl with cerebral palsy to her Sweetheart Formal leading to her now viral reaction finally made their way to formal together this weekend. 16-year-old Bryce asked Madison to accompany him to the formal earlier this month, nearly bringing Madison and her family to tears. It's likely every mom's dream for their daughter, but Samantha Kelly thought it would never happen her little girl 15-year-old Madison because she has Cerebral Palsy. "I wanted to cry," said Madisons mother said after Bryce asked her daughter to the dance. DyneshiaBellamy is Madison's nurse. She came up with the idea for her 16-year-old son Bryce to ask Madison to the sweetheart ball for people with disabilities. Bryce agreed and went all out with a sign and flowers asking Madison to the dance. WATCH: Local boy asks girl with cerebral palsy to Sweetheart Formal Over Memorial Day Weekend, Bryce escorted Madison to their formal, only this time he wasn't acting alone. The Middle Township Police and Rescue Squad provided a police escort to the formal at the Wildwood Convention. Samantha tells FOX 29 a large number of other departments including Green Creek Fire Company, Rio … Continue reading →

Posted in Cerebral Palsy | Comments Off on Local boy, police accompany teen with cerebral palsy to formal – FOX 29 News Philadelphia

InVivo Therapeutics Announces Update to the Contemporary Thoracic SCI Registry Study (the CONTEMPO Registry … – Business Wire (press release)

Posted: Published on May 30th, 2017

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV)today announced that data from the Christopher & Dana Reeve Foundation NACTN Registry will be included in the Contemporary Thoracic SCI Registry Study (now called the CONTEMPO Registry Study), a complement to the ongoing INSPIRE study of the Neuro-Spinal Scaffold. The CONTEMPO Registry Study is intended to provide comprehensive natural history benchmarks for INSPIRE study results that include spinal cord injury (SCI) patients with similar baseline characteristics treated since 2006. The NACTN registry is derived from a network of academic neurosurgical departments of hospitals that have a strong focus on SCI, especially in the acute injury phase. The NACTN Registry includes acute patient data such as pre- and post-operative data, post-injury complications and treatments, MRI data, and follow-up neurological exams. Because the NACTN registry contains acute care data, it will allow for the close matching of registry patient characteristics with INSPIRE inclusion and exclusion criteria, and will be highlighted in the CONTEMPO Registry Study as a well matched natural history benchmark comparator for INSPIRE results. The CONTEMPO Registry Study will provide a robust evaluation of the recent natural history of acute, complete thoracic SCI patients across North American and European populations. InVivo has submitted … Continue reading →

Posted in Spinal Cord Injury Treatment | Comments Off on InVivo Therapeutics Announces Update to the Contemporary Thoracic SCI Registry Study (the CONTEMPO Registry … – Business Wire (press release)

INVIVO THERAPEUTICS HOLDINGS CORP. (NASDAQ:NVIV) Files An 8-K Regulation FD Disclosure – Market Exclusive

Posted: Published on May 30th, 2017

INVIVO THERAPEUTICS HOLDINGS CORP. (NASDAQ:NVIV) Files An 8-K Regulation FD Disclosure Item7.01. Regulation FD Disclosure. On May30, 2017,InVivo Therapeutics Holdings Corp. (the Company) posted an updated corporate presentation in the Investor Relations section of its website at http://www.invivotherapeutics.com. On the same date, the Company posted an updated CEOs Perspective in the About InVivo section of its website. About INVIVO THERAPEUTICS HOLDINGS CORP. (NASDAQ:NVIV) InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Companys approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI. … Continue reading →

Posted in Spinal Cord Injury Treatment | Comments Off on INVIVO THERAPEUTICS HOLDINGS CORP. (NASDAQ:NVIV) Files An 8-K Regulation FD Disclosure – Market Exclusive

Parkinson’s Disease Forecast and Market Analysis to 2035 – Market is Dominated by Generics – GlobeNewswire (press release)

Posted: Published on May 30th, 2017

May 30, 2017 04:33 ET | Source: Research and Markets Dublin, May 30, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Parkinson's Disease Forecast and Market Analysis to 2035" report to their offering. Sizable pipeline characterized by both high growth and attrition Parkinson's disease is a chronic and progressive neurodegenerative disorder characterized by tremors, rigidity, bradykinesia (slowness of movement), and postural instability. Patients also experience significant non-motor symptoms including changes in cognition and mood, sleep disturbances, and autonomic dysfunction. The condition is caused by the degeneration of dopamine-producing cells of the substantia nigra. Parkinson's disease is incurable, but non-fatal, resulting in poor quality of life and increasing disability as the disease progresses. Studies classify Parkinson's disease as the second most common neurologic disease following Alzheimer's disease, and it is expected to cause an increasing social and economic burden as populations age. Recent events and opinion Parkinson's disease is predominantly treated with longstanding and mature therapies such as levodopa and the dopamine agonists, pramipexole and ropinirole. The market is therefore dominated by generics, with Teva's Azilect (rasagiline) being the last lucrative drug indicated for all Parkinson's disease patients. Drug developers have responded by introducing new treatment … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Parkinson’s Disease Forecast and Market Analysis to 2035 – Market is Dominated by Generics – GlobeNewswire (press release)

Is Exercise A Key Treatment For People With Multiple Sclerosis? These Penn Medicine Specialists Say Yes – Philadelphia magazine

Posted: Published on May 30th, 2017

Photo credit: Getty Images/aykuterd For people who suffer from multiple sclerosis (MS), some days the pain can make it your instinct to curl into a ball and stay in bed. But, according to the certified MS specialists at Penn Medicine, that is actually the opposite of what you should do. Their work finds exercise is actually one of the most important parts of treatment for people with MS. If you think exercising with MS sounds crazy, youre not alone. Many MS patients avoid exercise, thinking it will aggravate pain or worsen their fatigue. Research shows the opposite is trueexercise can actually improve symptoms, according to Diana Duda, PT, DPT, MSCS. Diana is a physical therapist at Penn Therapy and Fitness at Rittenhouse and a Multiple Sclerosis Certified-specialist who treats patients will all types of MS along the continuum of the disease process. Diana answers some commonly asked questions below and explains why exercise is so important for a patient with MS. Q: Exercise is always important for good health. What makes it especially important for patients with MS? Regular, moderate physical exercise is good for the body, mind, and mood and this is very true for patients with MS. When … Continue reading →

Posted in MS Treatment | Comments Off on Is Exercise A Key Treatment For People With Multiple Sclerosis? These Penn Medicine Specialists Say Yes – Philadelphia magazine

#CMSC17 Review Suggests Certain MS Patient Groups May Discontinue Disease-Modifying Treatments – Multiple Sclerosis News Today

Posted: Published on May 30th, 2017

vF(9{{zlMc0p/+?x(7Sp*XEpLE9A(W/~%IvTUnmq{ATaFbwM,qkB];&w8{U uTQmUlwt2#x83 AdX{MidL/c5x_B;82+e6{p+|eC">^fj#v#UW{V$?&CEb|c!.II4XNu9!F;ZK{~~llZ@Z[~kin@>vu+*A{61@/h /WI ^QMXj'%Vw I|rA2l9T{Y0aWI O,wH}'=YW; Co$w+cC7ZsUlhEg O#Lq!}4qS=F9)l&`hFz-0S0UCR^G;tkyN`6UNx7 hFwAivsM*u@YQvaUQaF)64uZUYsc]ILsuy=],gfzlN^JQ6,6+BJ'}$cNT.8IY% [d^g-PUT,K(JS|S)>$U^%[ eZrk j%"#_Jo9})O NAld: M :h?`:^>Q>?$*7{D,RrYup_l![eaW- kEA; K11haD2`*'"aL5y~)6fw=gg'?7X]bmvFShXpAXcLm,y;w] h{N,g2`)s *zI$U".*7A|oe,$Ypdl9|E;V NULHyd2)C[0v0B,MILP}rX6"gqA?@,vZbG>/#E Vx38ETL fn*jpgl?xZ(tUTO*vZd[QR^0`P }4w'9ir0 cqI^mlS;} v[.F7*Q5O=od;.fxHsq/mm$k~6?.EB 9&&/ ?Ip]W7,R(>"'i&+Tl FPo4MYWo^`^zefP/3P{&jM3Cz^#a5H-G{"FKXo%l!d2(65BBo7Pu; arJR4MvQlFkf#4Fbgi''m7=V^"Kuw6a3;E> '{VV&NTL,KWPz h e`4S^1LYfMSC5YAnwp*CasSaO#{*bDfj*Z-to_F ,o:- !>8h7FDCzHm|1c;g>b$3`GUK@Ot-d00@ B|K h{.QNonSj>5{j(dL4Lo'y[CM )7=[MF.Tb7T[HSG ?]a iV6_j>G9%$/`eIh[EJ/ "?[f5w3#cNv;vCK^(2 FL-.][vhJ'RM]t)klrBY#d4H9e] # C&^]ex& .L>tu=': ':eaK~Rma @(2RydDKa$~J'jNR iy2Gy%'CqHx xw i&V4 zG3i … Continue reading →

Posted in MS Treatment | Comments Off on #CMSC17 Review Suggests Certain MS Patient Groups May Discontinue Disease-Modifying Treatments – Multiple Sclerosis News Today

Page 1,740«..1020..1,7391,7401,7411,742..1,7501,760..»